Trailing-twelve-month (TTM) revenue is $2.68 Billion with a year-over-year growth of (2.09%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $701,300,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $660,500,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $636,500,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $678,200,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-29 |
| TTM revenue | $2,676,500,000 |
Current P/S: $1,902,000,000 market capitalization ÷ $2,676,500,000 TTM revenue = 0.71x.
Market capitalization source: FMP quote. Quote observed 2026-10-02T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $678.20M.
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 14 comparable quarters.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-03T00:15:29.228Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-02.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|
| Clinical Services Segment | $2.8B | $2.7B | $2.7B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|
| Europe | $828M | $800M | $852M |
| North America | $1.7B | $1.3B | $1.3B |
| Other Geographical Areas | $618M | $627M | $582M |
$2.68B
$2.68 Billion
(2.09%)
vs. $2.73B a year ago (TTM)
+1.09%
5 Year compound annual growth rate
1 Year
(2.09%)
3 Year
+0.56%
5 Year
+1.09%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.72B | +$27.00M | +1.00% |
| 2024 | $2.70B | ($146.10M) | (5.14%) |
| 2023 | $2.84B | +$5.50M | +0.19% |
| 2022 | $2.84B | ($220.50M) | (7.21%) |
| 2021 | $3.06B | +$477.20M | +18.49% |
TTM Growth
(2.09%)
3-Year CAGR
+0.56%
5-Year CAGR
+1.09%
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-03T00:15:29.228Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-02.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
